AAV
Showing 376 - 397 of 397
ANCA-associated Vasculitis Trial in London (Abatacept (Orencia))
Terminated
- ANCA-associated Vasculitis
- Abatacept (Orencia)
-
London, United KingdomImperial College London, Hammersmith Hospital
May 28, 2015
PRO Development for ANCA Associated Vasculitis
Unknown status
- Wegener Granulomatosis
- +2 more
-
Oxford, Oxfordshire, United KingdomUniversity of Oxford
May 27, 2015
CHF, Dilated Cardiomyopathy Trial in United States (MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo
Completed
- Heart Failure, Congestive
- Dilated Cardiomyopathy
- MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
- +2 more
-
San Diego, California
- +21 more
Aug 19, 2014
Parkinson's Disease Trial in San Francisco (AAV-hAADC-2)
Completed
- Parkinson's Disease
- AAV-hAADC-2
-
San Francisco, CaliforniaUniversity of California, San Francisco
Dec 2, 2013
Multiple Myeloma Trial in Durham (Arsenic Trioxide, Ascorbic Acid and Bortezomib)
Terminated
- Multiple Myeloma
- Arsenic Trioxide, Ascorbic Acid and Bortezomib
-
Durham, North CarolinaDuke University Medical Center
Jan 7, 2014
Acute Intermittent Porphyria Trial in Pamplona, Madrid (rAAV2/5-PBGD vector dosage 1, rAAV2/5-PBGD vector dosage 2, rAAV2/5-PBGD
Completed
- Acute Intermittent Porphyria
- rAAV2/5-PBGD vector dosage 1
- +3 more
-
Pamplona, Navarra, Spain
- +1 more
Dec 17, 2014
HIV Infection Trial in Belgium, Germany, India (tgAAC09)
Completed
- HIV Infection
- tgAAC09
-
Antwerpen, Belgium
- +4 more
Jan 14, 2013
Observational Study of Acute Intermittent Porphyria Patients
Completed
- Acute Intermittent Porphyria
-
Pamplona, Navarra, Spain
- +1 more
Mar 11, 2014
Human Immunodeficiency Virus Infections, HIV Trial in South Africa, Uganda, Zambia (tgAAC09, Formulation buffer)
Completed
- Human Immunodeficiency Virus Infections
- HIV Infections
- tgAAC09
- Formulation buffer
-
Cape Town, South Africa
- +4 more
Dec 13, 2012
Duchenne Muscular Dystrophy Trial in Columbus (rAAV2.5-CMV-minidystrophin (d3990))
Completed
- Duchenne Muscular Dystrophy
- rAAV2.5-CMV-minidystrophin (d3990)
-
Columbus, OhioColumbus Children's Hospital
Feb 4, 2013
Muscular Dystrophies Trial in Columbus (rAAV1.tMCK.human-alpha-sarcoglycan- First cohort, Genetic:
Completed
- Muscular Dystrophies
- rAAV1.tMCK.human-alpha-sarcoglycan- First cohort
- Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort
-
Columbus, OhioThe Research Institute at Nationwide Children's Hospital
Feb 4, 2013
Parkinson's Disease Trial in United States (Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus)
Terminated
- Parkinson's Disease
- Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus
-
Stanford, California
- +6 more
Feb 20, 2012
Limb Girdle Muscular Dystrophy Type 2C, Gamma-sarcoglycanopathy Trial in Paris (AAV1-gamma-sarcoglycan vector injection)
Completed
- Limb Girdle Muscular Dystrophy Type 2C
- Gamma-sarcoglycanopathy
- AAV1-gamma-sarcoglycan vector injection
-
Paris, FranceHôpital Pitié-Salpêtrière
Apr 28, 2011
Long Term Follow-Up Study for rAAV-GAD Treated Subjects
Terminated
- Parkinson's Disease
- rAAV-GAD
-
Stanford, California
- +5 more
Feb 20, 2012
Familial Lipoprotein Lipase Deficiency Trial in Chicoutimi, Quebec (Alipogene Tiparvovec (AMT-011), Human LPL [S447X],
Completed
- Familial Lipoprotein Lipase Deficiency
- Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
- +3 more
-
Chicoutimi, Quebec, Canada
- +1 more
Sep 28, 2011
Familial Lipoprotein Lipase Deficiency Trial in Chicoutimi (Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Mycophenolate
Unknown status
- Familial Lipoprotein Lipase Deficiency
- Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
- +2 more
-
Chicoutimi, Quebec, CanadaEcogene-21 Clinical Trial Center/ Centre de santé et de services
Sep 29, 2011
Vasculitis, Microscopic Polyangiitis, Granulomatosis With Polyangiitis Trial in Cambridge (Alemtuzumab)
Unknown status
- Vasculitis
- +3 more
-
Cambridge, United KingdomAddenbrooke's Hospital, University of Cambridge NHS Foundation T
Jul 28, 2011
Arthritis, Rheumatoid, Arthritis, Psoriatic, Ankylosing Spondylitis Trial in United States (tgAAC94 gene therapy vector, tgAAC94
Completed
- Arthritis, Rheumatoid
- +2 more
- tgAAC94 gene therapy vector
- tgAAC94 placebo
-
Glendale, Arizona
- +21 more
Jul 27, 2009
Prostate Cancer Trial in Portland (GM-CSF gene transduced allogeneic vaccine GVAX)
Unknown status
- Prostate Cancer
- GM-CSF gene transduced allogeneic vaccine GVAX
-
Portland, OregonProvidence Portland Medical Center
Feb 23, 2009
Parkinson's Disease Trial in Manhasset (Surgical infusion of AAV-GAD into the subthalamic nucleus)
Completed
- Parkinson's Disease
- Surgical infusion of AAV-GAD into the subthalamic nucleus
-
Manhasset, New YorkNorth Shore University Hospital
Mar 26, 2008
Rheumatoid Arthritis Trial in Canada, United States (tgAAC94 gene therapy vector, tgAAC94 )
Completed
- Rheumatoid Arthritis
- tgAAC94 gene therapy vector
- tgAAC94 placebo
-
Los Angeles, California
- +6 more
Feb 5, 2008
Hemophilia B Trial in Palo Alto, Philadelphia, Pittsburgh (Adeno-Associated Viral with Human Factor IX)
Terminated
- Hemophilia B
- Adeno-Associated Viral with Human Factor IX
-
Palo Alto, California
- +2 more
Apr 2, 2007